Formulations for treating ocular diseases and conditions
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
A61K-031/44
A01N-043/42
출원번호
US-0193686
(2008-08-18)
등록번호
US-8663639
(2014-03-04)
발명자
/ 주소
Dor, Philippe J. M.
Mudumba, Sreenivasu
Nivaggioli, Thierry
Weber, David A.
Farooq, Sidiq
Takhar, Sudeep
출원인 / 주소
Santen Pharmaceutical Co., Ltd.
대리인 / 주소
Morrison & Foerster LLP
인용정보
피인용 횟수 :
1인용 특허 :
137
초록▼
Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which del
Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.
대표청구항▼
1. A method for treating wet age-related macular degeneration in a human subject by repeated administration of a first formulation and a second formulation, the method comprising: (a) administering to the human subject two or more doses of a volume of the first formulation by intravitreal placement,
1. A method for treating wet age-related macular degeneration in a human subject by repeated administration of a first formulation and a second formulation, the method comprising: (a) administering to the human subject two or more doses of a volume of the first formulation by intravitreal placement, wherein the volume of the first formulation comprises an amount of and about 500 μg of ranibizumab; and(b) administering to the human subject two or more doses of a volume of the second formulation by intravitreal or subconjuctival placement, wherein the volume of the second formulation comprises an amount of between about 200 μg and about 2000 μg of rapamycin, or a pharmaceutically acceptable salt or ester thereof;wherein the administration of rapamycin or a pharmaceutically acceptable salt or ester thereof decreases the frequency at which ranibizumab is administered to treat wet age-related macular degeneration in the human subject. 2. The method of claim 1, wherein step (a) is coincident with step (b). 3. The method of claim 1, wherein step (b) is subsequent to step (a). 4. The method of claim 1, wherein step (b) is prior to step (a). 5. The method of claim 1, wherein the volume of the second formulation contains a rapamycin dose selected from the group consisting of about 220 μg, about 440 μg, about 880 μg, and about 1320 μg of rapamycin. 6. The method of claim 1, wherein the second formulation is a liquid solution that consists essentially of about 2% (w/w) rapamycin, about 4% (w/w) ethanol, and about 94% (w/w) polyethylene glycol 400 (PEG 400). 7. The method of claim 1, wherein the second formulation is a liquid solution that consists essentially of about 4% (w/w) rapamycin, about 4% (w/w) ethanol, and about 92% (w/w) polyethylene glycol 400 (PEG 400). 8. The method of claim 1, wherein the second formulation is a liquid solution that consists essentially of about 1% (w/w) rapamycin, about 4% (w/w) ethanol, and about 95% (w/w) polyethylene glycol 400 (PEG 400). 9. The method of claim 1, wherein the second formulation is a solution of rapamycin dissolved in a solvent system. 10. The method of claim 9, wherein the solvent system comprises polyethylene glycol. 11. The method of claim 10, wherein the solvent system further comprises ethanol.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (137)
Zhang,Mingqiang; Sheridan,Rose Mary, 39-desmethoxyrapamycin, compositions and methods of use thereof.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Osbakken,Robert S.; Hale,Mary Anne; Leivo,Frederick T.; Munk,James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Peyman Gholam A. (New Orleans LA) Yang Dachuan (New Orleans LA) Khoobehi Bahram (New Orleans LA), Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same.
Appel, Leah E.; Curatolo, William J.; Herbig, Scott M.; Nightingale, James A. S.; Thombre, Avinash G., Controlled release by extrusion of solid amorphous dispersions of drugs.
Goulet Mark (Westfield NJ) Beattie Thomas R. (Scotch Plains NJ) Wyvratt Matthew J. (Mountainside NJ), Fluoromacrolides having immunosuppressive activity.
Armistead David A. (Maynard) Boger Joshua S. (Concord) Meyers Harold V. (Lexington) Saunders Jeffrey O. (Littleton) Tung Roger D. (Cambridge MA), Immunosuppressive compounds.
Gregory, Susan A; Isakson, Peter C; Anderson, Gary, Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin.
Steiner Joseph P. (Hampstead MD) Snyder Solomon (Baltimore MD) Hamilton Gregory S. (Catonsville MD), Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth.
Mudumba, Sreenivasu; Dor, Philippe J M; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq, Liquid formulations for treatment of diseases or conditions.
Wright,Carol; Llanos,Gerard H.; Rakos,Ronald; King,Kristin; Falotico,Robert, Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent.
Luly Jay R. (Libertyville IL) Kawai Megumi (Libertyville IL) Or Yat S. (Libertyville IL) Wiedeman Paul (Libertyville IL) Wagner Rolf (Gurnee IL), Macrocyclic immunomodulators.
Calne Roy (22 Arrow Road Cambridge GB2 CB22AS), Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Organ Helen M. (Fanwood NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity.
Robinson, Michael R.; Csaky, Karl G.; Yuan, Peng; Sung, Cynthia; Nussenblatt, Robert B.; Smith, Janine A., Ocular therapeutic agent delivery devices and methods for making and using such devices.
Gerhard Zenke DE; Hendrik Schuurman CH; Barbara Haeberlin CH; Armin Meinzer DE, Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin.
Smith ; III Amos B. (Merion PA) Condon Stephen M. (Philadelphia PA) Leazer ; Jr. Johnnie L. (Philadelphia PA) Maleczka Robert E. (Media PA) McCauley John A. (Philadelphia PA) Leahy James W. (San Lean, Processes and intermediates for preparing macrocycles.
Failli Amedeo A. (Princeton Junction NJ) Kao Wenling (Paoli PA) Steffan Robert J. (Langhorne PA) Vogel Robert L. (Stratford NJ), Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents.
Waranis Robert P. (Chazy NY) Harrison Maureen M. (St. Albans VT) Leonard Thomas W. (Plattsburgh NY) Enever Robin P. (Rouses Point NY), Rapamycin formulation for IV injection.
Harrison Maureen M. (St. Albans VT) Ofslager Christian L. (Plattsburgh NY) Waranis Robert P. (Chazy NY) Leonard Thomas W. (Wilmington NC), Rapamycin formulations for oral administration.
Weiner Alan L. (Cranbury NJ) Sinnett Kevin (Mukwonago WI) Johnson Sterling (Skillman NJ), Tack for intraocular drug delivery and method for inserting and removing same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.